A number of other research firms have also issued reports on WVE. Zacks Investment Research upgraded Wave Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, July 18th. Mizuho reiterated a “buy” rating and issued a $21.00 price objective on shares of Wave Life Sciences in a research note on Sunday, June 7th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Wave Life Sciences has an average rating of “Buy” and an average target price of $17.67.
Shares of WVE opened at $17.71 on Thursday. The company’s 50-day simple moving average is $10.95 and its 200-day simple moving average is $9.83. The company has a debt-to-equity ratio of 1.36, a quick ratio of 1.33 and a current ratio of 1.33. Wave Life Sciences has a 1 year low of $6.61 and a 1 year high of $39.98. The stock has a market capitalization of $645.60 million, a PE ratio of -3.13 and a beta of 0.19.
Wave Life Sciences (NASDAQ:WVE) last released its earnings results on Monday, August 10th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.03) by ($0.12). Wave Life Sciences had a negative return on equity of 401.32% and a negative net margin of 1,562.01%. The business had revenue of $3.03 million for the quarter, compared to analyst estimates of $7.04 million. On average, sell-side analysts predict that Wave Life Sciences will post -3.92 earnings per share for the current year.
In related news, CEO Paul Bolno sold 147,577 shares of Wave Life Sciences stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $10.30, for a total transaction of $1,520,043.10. Following the sale, the chief executive officer now directly owns 315,249 shares in the company, valued at approximately $3,247,064.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 38.20% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA grew its holdings in shares of Wave Life Sciences by 163.4% during the first quarter. BNP Paribas Arbitrage SA now owns 6,989 shares of the company’s stock worth $65,000 after buying an additional 4,336 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in Wave Life Sciences during the 2nd quarter worth approximately $104,000. SG Americas Securities LLC purchased a new position in shares of Wave Life Sciences in the 2nd quarter valued at approximately $116,000. Wells Fargo & Company MN increased its holdings in shares of Wave Life Sciences by 18.9% in the first quarter. Wells Fargo & Company MN now owns 15,120 shares of the company’s stock valued at $142,000 after purchasing an additional 2,407 shares during the period. Finally, Quantitative Systematic Strategies LLC purchased a new stake in shares of Wave Life Sciences during the second quarter worth approximately $179,000. Hedge funds and other institutional investors own 80.67% of the company’s stock.
Wave Life Sciences Company Profile
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Recommended Story: Dividend Aristocrat Index
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.